Back to Search
KYLIE PRICE, PHARMD
PHARMD
Pharmacist
NPI: 1487171252Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
RP0009293(WV)
Research & Publications (20)
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.
PMID 19280340·Breast Cancer Res Treat·2010
4-observational
Job satisfaction and burnout among staff working in community-based personality disorder services.
PMID 19592446·Int J Soc Psychiatry·2010
8-other
Factors associated with anemia in patients with cancer admitted to an intensive care unit.
PMID 19577413·J Crit Care·2010
8-other
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer.
PMID 19633051·Ann Oncol·2010
4-observational
Self-reported adverse events in health care that cause harm: a population-based survey.
PMID 19413518·Med J Aust·2009
8-other
Sustained low efficiency dialysis in the continuous mode (C-SLED): dialysis efficacy, clinical outcomes, and survival predictors in critically ill cancer patients.
PMID 19628685·Clin J Am Soc Nephrol·2009
8-other
Making breathing your business: enterprising practices at the margins of orthodoxy.
PMID 19366840·Health (London)·2009
8-other
Eyebrow and eyelid dimensions: an anthropometric analysis of African Americans and Caucasians.
PMID 19644282·Plast Reconstr Surg·2009
4-observational
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.
PMID 19468030·Ann Oncol·2009
4-observational
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.
PMID 19415952·Arch Pathol Lab Med·2009
4-observational
Membrane-targeted strategies for modulating APP and Abeta-mediated toxicity.
PMID 19278455·J Cell Mol Med·2009
6-review
Glutamine 57 at the complementary binding site face is a key determinant of morantel selectivity for {alpha}7 nicotinic receptors.
PMID 19506073·J Biol Chem·2009
8-other
Primary cultures of renal proximal tubule cells derived from individuals with primary hyperoxaluria.
PMID 19283374·Urol Res·2009
8-other
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
PMID 19528136·Clin Trials·2009
3-trial
Unraveling the genetic landscape of bladder development in mice.
PMID 19303107·J Urol·2009
7-preclinical
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
PMID 19474112·Ann Oncol·2009
3-trial
Identifying unit-specific nursing demands using Nursing Interventions Classification (NIC).
PMID 19592973·Stud Health Technol Inform·2009
8-other
Hormone replacement therapy diminishes hearing in peri-menopausal mice.
PMID 19269311·Hear Res·2009
7-preclinical
Life-supportive therapy withdrawal and length of stay in a large oncologic intensive care unit at the end of life.
PMID 19586391·J Palliat Med·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1200 J D ANDERSON DR
MORGANTOWN, WV 26505 - Phone
- (304) 598-1444
Quick Facts
- NPI
- 1487171252
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile